Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CC2205
- Development stage
- Preclinical
- Lead developer
- CirCode Bio
- Modality
- Vaccines & Immunotherapeutics, RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
CC2205 is a circular RNA (circRNA) vaccine candidate developed by CirCode Bio (环码生物) for the prevention of Herpes Zoster (shingles). Utilizing a proprietary circular RNA platform, CC2205 is designed to overcome the stability and translation limitations of traditional linear mRNA vaccines. Circular RNA is a covalently closed loop that lacks 5' and 3' ends, making it inherently resistant to exonuclease-mediated degradation and potentially providing a longer half-life and more sustained protein expression in vivo. CC2205 encodes a viral antigen, typically the Varicella-Zoster Virus (VZV) glycoprotein E, to stimulate a robust and durable immune response, including both neutralizing antibodies and T-cell activity. It is currently in preclinical development.
Beyond the preview
Go deeper on CC2205.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CC2205.